Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey

Abstract

Introduction

We explored patient satisfaction with baricitinib, an oral Janus kinase inhibitor, in patients with atopic dermatitis (AD) treated in routine clinical practice.

Methods

Adults with moderate-to-severe AD treated with baricitinib in clinical practice for ≥4 weeks in France, Germany, and the UK completed a one-time online survey under market research methodologies. Treatment satisfaction was assessed using a Likert scale and abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). Patients reported demographic, disease, and treatment information. Data were analyzed descriptively.

Results

The survey was completed by 170 patients with a mean age of 39.3 years (SD = 13.5), 59% (n = 101) were female. At baricitinib initiation, 79% rated their AD as “Severe”, yet 28% reported body surface area (BSA) involvement ≥10%. Most were “Satisfied” or “Very satisfied” (76%/18%) with baricitinib, with high rates reported for controlling itch (36%/56%). Itch improvements were noted by 97% of patients. Some tapered/stopped (50%/32%) topical corticosteroid use, aligned with reported improvements on the patient global assessment and BSA. Mean TSQM-9 convenience score was 78.0 (SD = 14.0).

Conclusions

Satisfaction with itch control was particularly high, reflected in rates of improvement in itch since starting baricitinib. On the TSQM-9, the convenience score was the highest. Many patients tapered/stopped concomitant topicals, indicating baricitinib’s effect in controlling AD symptoms.

Keywords:

• Atopic dermatitis
• patient-centered care
• oral Janus kinase inhibitors
• baricitinib
• patient satisfaction

Acknowledgements

The authors would like to thank the participants of the study for their time and contribution to the work. Without their participation, this study would not have been possible.

Author contributions

All authors contributed to the interpretation of the data, the drafting of the manuscript, and provided critical revisions to the work for important intellectual content.

Medical writing and editorial assistance

Mr. Alan Ó Céilleachair, an employee of Eli Lilly and Company, provided scientific writing and editorial support on the manuscript. This support was funded by Eli Lilly and Company.

Disclosure statement

MA has received grants from AbbVie, Almirall, Beiersdorf, Eli Lilly, Galderma, Incyte, LEO, Menlo, MSD, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Trevi; consulting fees from AbbVie, Almirall, Beiersdorf, Eli Lilly, Galderma, Incyte, LEO, Menlo, MSD, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Trevi; payments/honoraria from AbbVie, Almirall, Beiersdorf, Eli Lilly, Galderma, Incyte, LEO, Menlo, MSD, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Trevi.

AN has received grants from Sanofi, Regeneron, Pierre Fabre, Janssen Cilag, Celgene, Eli Lilly, Leo Pharma, Galderma, AbbVie; consulting fees from Sanofi Regeneron, Pierre Fabre, Novartis, Galderma, Pfizer, AbbVie, Eli Lilly, Leo Pharma, Medac, Almirall; payment/honoraria from ALK, Sanofi Regeneron, Novartis, AbbVie, Pierre Fabre, Eli Lilly, Medac, Pfizer, L’Oréal; meetings/travel support from Sanofi Regeneron, AbbVie, Janssen. She has participated on Advisory Boards for Sanofi Regeneron, AbbVie, Eli Lilly and Company, Pfizer, Leo Pharma.

TW has received payment for presentations from Eli Lilly, Sanofi-Regeneron, Abbvie, Pfizer, Galderma, Leo; participated on Advisory Boards for Eli Lilly, Sanofi-Regeneron, Abbvie, Pfizer, Galderma, Leo, holds office with German Societies for Dermatoloy (DDG)/Allergology (DGAKI).

ADI has received consulting fees from AbbVie, Eli Lilly, Pfizer, Benevolent AI, Arena, Novartis, Regeneron, Sanofi, Leo Pharma; payments/honoraria from Regeneron, Sanofi, AbbVie, Eli Lilly, Leo Pharma, Janssen; has a patent issued with Johnson and Johnson. He has participated on Advisory Boards for Novartis, OM Pharma. President Elect of the International Eczema Council.

SG, AL, CR, and NT are employees/minor shareholders of Eli Lilly.

ER, a former Eli Lilly employee, has received consulting fees from Eli Lilly, payments/honoraria from Eli Lilly, Pelpharma; and has been issued patents. The study, analysis and all costs relating to the publication of this manuscript, were funded by Eli Lilly and Company.

Data availability statement

The datasets generated during and/or analyzed during the current study are not publicly available as consent was not received from participants for the sharing of their data with third parties.

Notes

1 BSA involvement was determined based on the number of palms required to cover those parts of the patient’s body that were affected by their AD, with one palm = 1% body area coverage.